Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study-Reference-Cited by-同舟云学术

Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study

Published:2020-12 Issue:12 Volume:4 Page:1138-1145
ISSN:2468-6530
Container-title:Ophthalmology Retina
language:en
Short-container-title:Ophthalmology Retina

Author:

Bontzos Georgios,Bagheri Saghar,Ioanidi Larissa,Kim Ivana,Datseris Ioannis,Gragoudas Evangelos,Kabanarou Stamatina,Miller Joan,Tsilimbaris Miltiadis,Vavvas Demetrios G.

Funder

Amgen

Biogen Idec

Alcon

Valeant

Publisher

Elsevier BV

Subject

Ophthalmology

Reference42 articles.

1. VEGF: from discovery to therapy: The Champalimaud Award Lecture;Miller;Transl Vis Sci Technol,2016

2. Advances in age-related macular degeneration understanding and therapy;Miller;US Ophthalmic Rev,2017

3. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006

4. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study;Brown;Ophthalmology,2009

5. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravitreal faricimab for previously treated neovascular age-related macular degeneration;2024-06-26

2. Dual anti-angiogenic and anti-inflammatory action of tRNA-Cys-5-0007 in ocular vascular disease;Journal of Translational Medicine;2024-06-12

3. Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration;Eye;2024-01-26

4. Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration;Ophthalmology Retina;2023-10

5. Towards a population pharmacokinetic/pharmacodynamic model of anti-VEGF therapy in patients with age-related macular degeneration;European Journal of Pharmaceutics and Biopharmaceutics;2023-07